Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 14/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195751 | 0.87 | MEN1 (0.53) | MEN1KMT2ARAB9AMAPTHPGD | |
| SCHEMBL4198230 | 0.84 | ALOX15 (0.63) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL4199011 | 0.81 | NPC1 (0.53) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL4196298 | 0.81 | ALDH1A1 (0.46) | KCNMA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4198306 | 0.78 | ALOX15 (0.44) | KCNMA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4188965 | 0.77 | MEN1 (0.45) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL23246023 | 0.76 | NPC1 (0.53) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL9775410 | 0.76 | KCNMA1 (0.78) | KCNMA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28734370 | 0.74 | KCNMA1 (0.82) | KCNMA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28295632 | 0.73 | KCNMA1 (0.68) | KCNMA1MEN1KMT2AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088463-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088463-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX5, ALOX15B | KCNMA1 3619/4885MEN1 4164/4885KMT2A 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.